Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies

• Status: Not yet recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

It is important for patients treated with anti-EGFR therapies to get access to cosmetic options to preserve their skin condition during treatment. Anti-EGFR therapies are known to fragilize epidermis and to provoke rashes; which often lead to treatment discontinuation.

The aim of this study is to demonstrate that the Onco-Rash cream is able to preserve skin condition without side effects. Decreasing skin toxicity is expected to improve patients' life and facilitate treatment follow-up.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospices Civils de Lyon

Criteria

Inclusion Criteria:

• Patient > 18 years old

• Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc).

• NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line treatment (gefitinib, erlotinib,afatinib, etc)

• Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab, panitumumab,….)

• Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first line treatment (cetuximab,…)

• Signed informed consent

• Social security affiliation

Exclusion Criteria:

• Pregnant or Breastfeeding patient

• Patient in age to procreate without an efficient contraceptive method

• Patient with previous experience of allergic or irritative contact dermatitis to components of the studied product

• Patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-EGFR

• Patients under radiotherapy 8 days prior the inclusion date

• Patient under immunotherapy 8 days prior the inclusion date

• Patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date

• Patient with antihistamines treatment 8 days prior the inclusion date

• Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or corticoids 5 days prior the inclusion date

• Participation to another interventional study

• Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( >2)

• Patient deprived of liberty or subjected to guardianship

• Impossibility to track and follow patient for geographical, social or psychiatric reasons.